Daily Ards Research Analysis
Analyzed 13 papers and selected 3 impactful papers.
Summary
Three studies advance ARDS science and care: a pooled analysis shows that predicted body weight-based tidal volumes disproportionately expose women to higher driving pressures and mortality risk; a mechanistic study identifies 4-octyl itaconate as an Nrf2-dependent inhibitor of caspase-11-mediated macrophage pyroptosis in experimental ALI/ARDS; and an international cohort delineates outcomes and failure modes of ECMO without invasive ventilation, guiding patient selection and timing.
Research Themes
- Sex-specific lung-protective ventilation in ARDS
- ECMO without invasive mechanical ventilation: selection and timing
- Immunometabolic modulation of pyroptosis in ALI/ARDS
Selected Articles
1. The predicted body weight equation overestimates lung sizes of female, critically ill patients: an analysis of randomized, controlled trials and real-world clinical data.
Across 30,516 ventilated ICU patients, PBW-standardized tidal volumes were associated with a higher absolute risk of high driving pressures in women, mediating increased 28-day mortality. At the same PBW, women had smaller anatomical and aerated lung volumes than men, challenging current PBW-based dosing and supporting driving pressure-guided personalization.
Impact: This large, methodologically rigorous synthesis links a ubiquitous bedside practice (PBW-based Vt) to sex-specific lung stress and mortality mediation, highlighting a modifiable source of harm.
Clinical Implications: Consider prioritizing driving pressure-guided ventilation targets and reassessing PBW-based tidal volume prescriptions in women; implement bedside monitoring to avoid driving pressure ≥15 cmH2O.
Key Findings
- With comparable ml/kg PBW, females had a 4.2% higher absolute risk of high driving pressures (aOR 1.26; 95% CI 1.19–1.33; p<0.001).
- Mediation analysis indicated that excess high driving pressures accounted for 8.4% of the increased 28-day mortality in females (p<0.001).
- At the same PBW, females had lower anatomical (-343 ml) and aerated (-188 ml) lung volumes than males (both p<0.001).
- Analysis included 30,516 ventilated ICU patients from 10 RCTs and 2 real-world cohorts.
Methodological Strengths
- Very large pooled dataset from randomized trials and real-world cohorts with consistent analytic framework
- Adjusted models with mediation analysis and clinically relevant outcomes (driving pressure, 28-day mortality)
Limitations
- Secondary/observational analyses limit causal inference and are prone to residual confounding
- PBW relies on anthropometry; measurement errors and heterogeneity across ICUs may affect generalizability
Future Directions: Prospective trials of driving pressure-guided or lung-volume-informed ventilation, and development of sex-adjusted PBW or alternative scaling metrics.
PURPOSE: Low tidal volume (Vt) ventilation is the standard of care among critically ill patients. Guidelines recommend scaling Vt to the predicted body weight (PBW) to avoid ventilator-induced lung injury (VILI). Concerns exist that the PBW overestimates lung volumes of critically ill females. We investigated whether this applies to clinically relevant measures of lung volume, whether PBW-guided mechanical ventilation yields comparable risk of lung stress among male and female patients, and whether this affects mortality. METHODS: Mechanically ventilated, critically ill patients from ten randomized trials and two real-world retrospective clinical datasets were analyzed. Risk of high driving pressures (≥ 15 cmH RESULTS: Among 30,516 patients (39.4% female), ventilation with comparable tidal volumes standardized to PBW (ml/kg PBW) was associated with 4.2% (95% CI 3.2-5.3; aOR 1.26, 95% CI 1.19-1.33; p < 0.001) higher absolute risk of high driving pressures among females, mediating 8.4% of excess 28-day mortality (p < 0.001). At the same PBW, female patients had lower anatomical and aerated lung volumes (- 343 ml, 95% CI - 449 to - 237, p < 0.001; and - 188, 95% CI - 282 to - 94, p < 0.001, respectively) than males. CONCLUSIONS: The widely used PBW equation overestimates lung volumes in female critically ill patients, resulting in excess risk of injurious driving pressures among females, mediating higher mortality. Personalized mechanical ventilation by using driving pressure-guided strategies might mitigate these disparities.
2. 4-Octyl itaconate-induced Nrf2 nuclear translocation mitigates Caspase-11-dependent noncanonical macrophage pyroptosis and acute lung injury.
4-Octyl itaconate reduced macrophage pyroptosis markers (PI positivity, GSDMD-NT) and ameliorated lung edema, cytokine release, and histologic injury in CLP-induced septic mice. Mechanistically, Nrf2 activation suppressed Casp4 transcription, limiting caspase-11-dependent noncanonical pyroptosis and identifying a druggable axis for ALI/ARDS.
Impact: It uncovers a mechanistic Nrf2–Caspase-11 axis controlling noncanonical pyroptosis and demonstrates a small-molecule modulator (4-OI) that mitigates experimental ALI/ARDS, advancing translational targets.
Clinical Implications: While preclinical, these data support exploring Nrf2 activation and caspase-11 pathway inhibition as adjunctive anti-inflammatory strategies in sepsis-related ALI/ARDS.
Key Findings
- 4-OI decreased PI-positive cells and GSDMD-NT fluorescence in LPS-stimulated macrophages, indicating inhibition of pyroptotic pore formation.
- In CLP-induced septic mice, 4-OI reduced lung edema, cytokine release, and histologic injury.
- Nrf2 activation suppressed Casp4 transcription, limiting caspase-11-dependent noncanonical pyroptosis; effects were probed using the Nrf2 inhibitor ML385.
Methodological Strengths
- Multi-system validation across in vitro (RAW264.7, BMDMs) and in vivo (CLP-induced sepsis) models
- Mechanistic interrogation with pathway perturbation (Nrf2 inhibitor) and molecular readouts (GSDMD-NT, IL-1β p17)
Limitations
- Preclinical models may not fully predict human efficacy and safety
- Reliance on murine cells/CLP model and cell lines limits direct clinical translatability and dosing guidance
Future Directions: Validate in human alveolar macrophages and translational ARDS biospecimens; define PK/PD and safety of 4-OI or analogs; test in larger animal lung injury models and as adjunct to standard care.
INTRODUCTION: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe inflammatory conditions, with mortality rates reaching 40%. A key driver of their pathogenesis is macrophage pyroptosis, which results in excessive inflammation and tissue damage. OBJECTIVES: The aim of this study was to investigate the regulatory effect and underlying mechanism of the itaconate derivative 4-octyl itaconate (4-OI) on macrophage pyroptosis and sepsis-induced ALI/ARDS. METHODS: The study employed a cecal ligation and puncture (CLP)-induced septic mouse model and LPS-stimulated RAW264.7 cells, and bone marrow-derived macrophages. Pyroptosis was assessed using propidium iodide (PI) staining to detect membrane pore formation, as well as quantitative fluorescence analysis and immunohistochemical quantitative analysis of GSDMD-NT. Additional evaluations included the western blot analysis of pyroptosis-related proteins (GSDMD-NT, IL-1β p17). Mechanistic insights were explored using the Nrf2 inhibitor ML385, Acod1 RESULTS: Based on the increase induced by LPS stimulation, 4-OI significantly reduced the proportion of PI-positive cells and also decreased the fluorescence expression of GSDMD-NT, thereby confirming its inhibition of pyroptotic pore formation. It alleviated pulmonary edema, cytokine release, and histological damage in CLP-induced septic mice. Mechanistically, Nrf2 specifically inhibited the transcription of Casp4, thereby reducing Caspase-11-dependent non-canonical macrophage pyroptosis. Casp4 CONCLUSION: The results demonstrate that 4-OI effectively inhibits Caspase-11-mediated pyroptosis and subsequent inflammation in experimental ALI/ARDS. This effect is mechanistically dependent on the activation of the Nrf2-Caspase-11 axis. The study thus identifies a novel therapeutic strategy whereby 4-OI targets pyroptotic pore formation, offering a potential therapeutic intervention for ALI/ARDS.
3. Extracorporeal membrane oxygenation without invasive mechanical ventilation for acute respiratory distress syndrome: an international cohort study.
In 307 ARDS patients supported with ECMO without IMV, 90-day mortality was higher with primary awake ECMO (30.1%) than extubated ECMO (14.9%). Strategy failure—often within 10 days—was strongly associated with mortality, with leading causes including respiratory worsening and agitation/delirium or secretion clearance issues.
Impact: This multicenter study delineates real-world risks, timing, and failure modes of ECMO without IMV, informing selection, cannulation timing, and bundle care to reduce mortality.
Clinical Implications: Prioritize early cannulation in appropriate candidates, monitor closely in the first 10 days, and implement protocols to prevent agitation/delirium and optimize secretion clearance to avoid strategy failure.
Key Findings
- 90-day mortality: 30.1% with primary awake ECMO vs 14.9% with extubated ECMO.
- Strategy failure occurred in 40.7% (awake) and 24.2% (extubated), most within 10 days of ECMO initiation.
- Strategy failure strongly associated with 90-day mortality (HR 7.67 [3.44–17.11] extubated; HR 5.95 [2.63–13.46] awake; both P<.001).
- Higher age (extubated) and longer time from ICU admission to cannulation (awake) associated with mortality; leading failure causes were respiratory worsening, agitation/delirium (awake), and secretion clearance issues (extubated).
Methodological Strengths
- International multicenter cohort with standardized outcomes and time-to-event analyses
- Multivariable modeling identifying predictors of mortality and strategy failure
Limitations
- Retrospective design with potential selection bias and center heterogeneity
- No randomized comparator to conventional ECMO with IMV; residual confounding possible
Future Directions: Prospective trials to define selection criteria, timing of cannulation, and standardized bundles (sedation, delirium prevention, secretion management) to reduce strategy failure.
RATIONALE: In acute respiratory distress syndrome (ARDS), extracorporeal membrane oxygenation (ECMO) without invasive mechanical ventilation (IMV) is particularly challenging. OBJECTIVES: To study ARDS patients treated with ECMO to avoid IMV-'primary awake ECMO'-or with extubation during ECMO support - 'extubated ECMO'. METHODS: International retrospective cohort of adult ARDS patients treated with ECMO without IMV at 14 centers in 8 countries (2015-2024). The primary outcome was mortality 90 days after ECMO initiation. MEASUREMENTS AND MAIN RESULTS: Among 307 adult patients with ARDS, 113 received 'primary awake ECMO' and 194 were extubated on ECMO. Ninety-day mortality was 30.1% in the 'primary awake ECMO' group and 14.9% in the 'extubated ECMO'. Strategy failure occurred in 46 patients (40.7%) and 47 patients (24.2%), respectively, most frequently within the first 10 days. In multivariate analysis, strategy failure was associated with 90-day mortality (hazard ratio 7.67 (3.44-17.11); P < .001 in 'extubated ECMO'; hazard ratio 5.95 (2.63-13.46); P < .001 in 'primary awake ECMO'), while higher age and longer time from ICU admission to ECMO cannulation were associated with 90-day mortality in 'extubated ECMO' and 'primary awake ECMO', respectively. The leading cause of strategy failure was worsening of respiratory failure, followed by agitation/delirium in 'primary awake ECMO' and inability to clear secretions in 'extubated ECMO'. CONCLUSIONS: Patients selected for 'primary awake ECMO' and 'extubated ECMO' presented different baseline characteristics, strategy failure, and 90-day mortality rates. However, strategy failure was consistently associated with 90-day mortality in both groups.